Clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + pegylated liposomal doxorubicin showed no clear difference in clinical response compared with HAART alone (moderate certainty).
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eye
1 finding from 1 review
Ocular surface staining · people with dry eye
1 finding from 1 review
Aqueous tear production · people with dry eye
1 finding from 1 review
Tear film stability · people with dry eye
1 finding from 1 review
Conjunctival goblet cell density (cells per unit) at 6 months · people with dry eye
1 finding from 1 review
Treatment related adverse events, · people with dry eye
1 finding from 1 review
All‐cause mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse events or complications · people with liver metastases
1 finding from 1 review
Disease-free survival · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to clear liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Proportion of participants with re‐epithelialization and complete healing with or without scar formation at 4 to 8 weeks Assessed by slit‐lamp biomicroscopy · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
15 participants
Very low
Proportion of participants with BCVA of 20/100 or better at 4 to 8 weeks Assessed using a logMAR chart · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
12 participants
Very low
Mean change from baseline in BCVA at 4 to 8 weeks Assessed using a logMAR chart · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Proportion of participants with a reduction in corneal infiltrate at 4 to 8 weeks Assessed by outcome assessors · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Proportion of participants with reduction in intraocular inflammation at 4 to 8 weeks Assessed by corneal keratic precipitates, anterior chamber cellular reaction, or other appropriate measure · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported